Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human Cathepsin S Antibodies:
anti-Mouse (Murine) Cathepsin S Antibodies:
anti-Rat (Rattus) Cathepsin S Antibodies:
Go to our pre-filtered search.
Human Polyclonal Cathepsin S Primary Antibody for IP, IHC - ABIN223091
Zaehringer, Sapoval, Pattynama, Rabbia, Vignali, Maleux, Boyer, Szczerbo-Trojanowska, Jaschke, Hafsahl, Downes, Beregi, Veeger, Stoll, Talen: Sirolimus-eluting versus bare-metal low-profile stent for renal artery treatment (GREAT Trial): angiographic follow-up after 6 months and clinical outcome up to 2 years. in Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists 2007
Show all 4 references for ABIN223091
Human Polyclonal Cathepsin S Primary Antibody for ICC, IF - ABIN4288275
Ma, Visser, Roelofsen, de Vries, Diepstra, van Imhoff, van der Wal, Luinge, Alvarez-Llamas, Vos, Poppema, Vonk, van den Berg: Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes. in Blood 2008
Show all 2 references for ABIN4288275
Human Polyclonal Cathepsin S Primary Antibody for EIA, WB - ABIN452893
Lindahl, Simonsson, Bergh, Thysell, Antti, Sund, Wikström: Increased levels of macrophage-secreted cathepsin S during prostate cancer progression in TRAMP mice and patients. in Cancer genomics & proteomics 2009
Show all 2 references for ABIN452893
levels of cathepsin S and hsCRP observed in women who later developed breast cancer may provide prognostic information regarding tumor development and need to be evaluated in prospective studies.
p41 (show EPB41 Antibodies) fragment is also shown to reduce the secretion of interleukin-12 (IL-12 (show IL12A Antibodies)/p70 (show ANXA6 Antibodies)) during the subsequent maturation of treated dendritic cells.
shedding of surface proteins by extracellular cathepsins impacts intracellular signaling as demonstrated for regulation of Ras GTPase (show RACGAP1 Antibodies) activity.
the essential role of autophagy-regulated early ROS (show ROS1 Antibodies) in triggering late apoptotic signaling
Cathepsin S cleaves near the N-terminus of PAR2 (show F2RL1 Antibodies) to expose a novel tethered ligand, KVDGTS.
Increased plasma CTSS concentration is associated with atherogenesis.
results identify Cat-S as a biased agonist of PAR2 (show F2RL1 Antibodies) that causes PAR2 (show F2RL1 Antibodies)- and TRPV4 (show TRPV4 Antibodies)-dependent inflammation and pain.
Its stability at neutral pH and potent proteolytic activity on extracellular matrix components mean that cathepsin S may contribute significantly to cartilage degradation and may thus be considered a potential drug target in joint diseases.
High cathepsin S expression at the primary site correlates with decreased brain metastasis-free survival in breast cancer patients.
cathepsin S and chemerin (show RARRES2 Antibodies) only correlated positively with insulin (show INS Antibodies) resistance and inflammation
Ctss induction during muscular dystrophy is a pathologic event that partially underlies disease pathogenesis, and its inhibition might serve as a new therapeutic strategy in Duchenne muscular dystrophy (show DMD Antibodies).
Demonstrate the utility of intracellular caspase 1 (show CASP1 Antibodies) and extracellular CTSS proteolytic activities as surrogate biomarkers of lysosomal rupture and acute inflammation.
Fluorogen substrate, Mca (show RSPH1 Antibodies)-GRWPPMGLPWE-Lys (show LYZ Antibodies)(Dnp)-DArg-NH2 can detect CTSS activities in mouse antigen presenting cells.
Data show that cathepsins S (CatS) regulates CCL2 (show CCL2 Antibodies) chemokine (show CCL1 Antibodies) expression by modulation of CD74 (show CD74 Antibodies) antigen processing.
Cathepsin S activates MrgprC11 (show MRGPRX1 Antibodies) and evokes receptor-dependent scratching in mice.
cathepsin S deficiency alters the balance between adipocyte and osteoblast differentiation, increases bone turnover, and changes bone microarchitecture. Therefore, bone and fat metabolisms should be monitored when using cathepsin S inhibitors clinically
Cathepsin S contributes to macrophage migration via degradation of elastic fibre integrity to facilitate neointima formation of vein grafts
cysteine cathepsins B and S can directly cleave Rip1 (show RALBP1 Antibodies)
CatS also reduced myocardial Smad2 (show SMAD2 Antibodies) and Smad3 (show SMAD3 Antibodies) activation and extra domain A fibronectin (show FN1 Antibodies) expression
These results, together with those previously reported for other genes of this family, suggest that cathepsin genes play a role in defining economically important traits in pigs.
The cathepsin S deserves further evaluation as therapeutic targets to develop disease modifying drugs to treat Alzheimer's disease.
The protein encoded by this gene, a member of the peptidase C1 family, is a lysosomal cysteine proteinase that may participate in the degradation of antigenic proteins to peptides for presentation on MHC class II molecules. The encoded protein can function as an elastase over a broad pH range in alveolar macrophages. Alternatively spliced transcript variants encoding distinct isoforms have been found for this gene.
, cathepsin S, gene 1
, Cathepsin S
, Cat S